Patent classifications
C07D241/10
Method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by heterogeneous cobalt catalysis
The invention discloses a method for preparation of alkylated, fluoro alkylated, chloro alkylated and fluorochloro alkylated compounds by a heterogeneous Co-catalysed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl halides, fluoro alkyl halides, chloro alkyl halides or fluorochloro alkyl halides respectively.
Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-N-protected amino ester
A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic -N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.
Formation of N-protected 3,6-bis-(4-aminobutyl)-2,5-diketopiperazine through a cyclic α-N-protected amino ester
A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic -N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.
Highly stable [MaMbF6-n(O/H2O)n(Ligand)2(solvent)x]n Metal Organic Frameworks
Embodiments of the present disclosure describe metal-organic framework compositions comprising a pillar characterized by the formula (M.sub.bF.sub.5(O/H.sub.2O)), where M.sub.b is selected from periodic groups IIIA, IIIB, IVB, VB, VIB, and VIII; and a square grid characterized by the formula (M.sub.a(ligand).sub.x), where M.sub.a is selected from periodic groups IB, IIA, IIB, IIIA, IVA, IVB, VIB, VIIB, and VIII, ligand is a polyfunctional organic ligand, and x is 1 or more; wherein the pillaring of the square grid with the pillars forms the metal-organic framework.
Highly stable [MaMbF6-n(O/H2O)n(Ligand)2(solvent)x]n Metal Organic Frameworks
Embodiments of the present disclosure describe metal-organic framework compositions comprising a pillar characterized by the formula (M.sub.bF.sub.5(O/H.sub.2O)), where M.sub.b is selected from periodic groups IIIA, IIIB, IVB, VB, VIB, and VIII; and a square grid characterized by the formula (M.sub.a(ligand).sub.x), where M.sub.a is selected from periodic groups IB, IIA, IIB, IIIA, IVA, IVB, VIB, VIIB, and VIII, ligand is a polyfunctional organic ligand, and x is 1 or more; wherein the pillaring of the square grid with the pillars forms the metal-organic framework.
Highly stable [MaMbF6-n(O/H2O)n(ligand)2(solvent)x]n metal organic frameworks
Embodiments of the present disclosure describe metal-organic framework compositions comprising a pillar characterized by the formula (M.sub.bF.sub.5(O/H.sub.2O)), where M.sub.b is selected from periodic groups IIIA, IIIB, IVB, VB, VIB, and VIII; and a square grid characterized by the formula (M.sub.a(ligand).sub.x), where M.sub.a is selected from periodic groups IB, IIA, IIB, IIIA, IVA, IVB, VIB, VIIB, and VIII, ligand is a polyfunctional organic ligand, and x is 1 or more; wherein the pillaring of the square grid with the pillars forms the metal-organic framework.
Highly stable [MaMbF6-n(O/H2O)n(ligand)2(solvent)x]n metal organic frameworks
Embodiments of the present disclosure describe metal-organic framework compositions comprising a pillar characterized by the formula (M.sub.bF.sub.5(O/H.sub.2O)), where M.sub.b is selected from periodic groups IIIA, IIIB, IVB, VB, VIB, and VIII; and a square grid characterized by the formula (M.sub.a(ligand).sub.x), where M.sub.a is selected from periodic groups IB, IIA, IIB, IIIA, IVA, IVB, VIB, VIIB, and VIII, ligand is a polyfunctional organic ligand, and x is 1 or more; wherein the pillaring of the square grid with the pillars forms the metal-organic framework.
PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
The invention provides a compound of Formula I,
##STR00001##
Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
The invention provides a compound of Formula I,
##STR00001##
Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
FORMATION OF N-PROTECTED 3,6-BIS-(4-AMINOBUTYL)-2,5-DIKETOPIPERAZINE THROUGH A CYCLIC ALPHA-N-PROTECTED AMINO ESTER
A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic -N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.